💬 Hot Topic: Are you loading up on LLY ahead of the oral weight-loss drug decision? Or are you sitting this one out? Let’s talk!
As April approaches, global pharmaceutical investors are zeroing in on one key date: April 10.
On that day, $Eli Lilly(LLY)$ will learn whether the U.S. Food and Drug Administration (FDA) approves its highly anticipated oral weight-loss drug, orforglipron.
For the drug giant — whose market cap once topped $1 trillion — this milestone carries massive weight, especially with its stock down roughly 19% from its late‑2025 all‑time high.
The Next Piece in Lilly’s Weight-Loss Dominance
Lilly’s leadership in the weight-loss market is already well established.
With tirzepatide — sold as Mounjaro for Type 2 diabetes and Zepbound for obesity — the company controls about 60% of the U.S. market.
In Q4 alone, these two drugs generated over $11 billion in combined revenue, both posting triple‑digit growth.
Yet reliance on injectables comes with risks.
Patients increasingly want convenience. Meanwhile, rival Novo Nordisk launched its own oral version of Wegovy in late 2025, even with strict fasting and meal restrictions.
That’s why orforglipron matters so much.
As Lilly’s oral GLP‑1 candidate, it delivered strong weight-loss results in clinical trials — and, crucially, requires no meal or water restrictions, making it far more convenient than existing alternatives.
For Lilly, the oral format also offers lower production and storage costs, supporting higher profit margins.
April 10: Catalyst … or “Good News Priced In”?
The FDA decision will clearly be a major short-term catalyst for Lilly’s stock.
Approval would open a major new growth pillar, especially with the global weight-loss market on track to approach $100 billion by 2030.
But the big debate among investors:
Has the market already priced in a win?
On one hand, LLY’s pullback from $1,133.95 has lowered its forward P/E to around 27x, making it more attractive than a few months ago.
On the other, concerns are rising about intensifying competition. Novo Nordisk’s steady pressure and new biotech entrants could erode Lilly’s pricing power and margins over time.
More Than Weight Loss: Lilly’s “Safety Net”
Even if weight-loss drug growth disappoints, Lilly is not a one‑product story.
Unlike Novo Nordisk, which depends heavily on GLP‑1s, Lilly has established pillars in oncology and immunology:
-
Breast cancer drug Verzenio: $5.7 billion in sales (+8% YoY)
-
Immunology drug Taltz: $3.6 billion in sales (+9% YoY)
The company also has a deep pipeline in pain management, oncology, and immunology through partnerships and internal R&D.
This diversification provides a strong safety cushion — even if weight-loss drugs hit a rough patch, Lilly can keep growing.
The Final Question: Buy Before April 10?
From a long-term perspective, Lilly’s core value remains intact.
Short-term traders should watch for the risk of a “sell-the-news” pullback if approval hits.
But for long-term investors, perfectly timing April 10 isn’t necessary.
As Mounjaro and Zepbound showed, truly great pharmaceutical value unfolds over years, not days.
In short:
If you believe in the long-term weight-loss megatrend and trust Lilly to maintain leadership through its product portfolio and pipeline, current levels offer strong long-term support — whether you buy before April 10 or after.
April 10 isn’t just a “buy or sell” moment.
It’s a key checkpoint to confirm whether Lilly’s next era of growth is officially underway.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Comments